To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: FDA Approves Over-The-Counter Tavist (Clemastine Fumarate) For Allergy, Sinus Headache URL: http://www.pslgroup.com/dg/1F487A.htm Doctor's Guide March 9, 2001
SUMMIT, NJ -- March 9, 2001 -- Novartis Consumer Health announced that the U.S. Food and Drug Administration (FDA) has granted approval of Tavist® Allergy/Sinus/Headache for marketing over-the-counter. Tavist Allergy/Sinus/Headache is the only over-the-counter medication to combine the antihistamine clemastine fumarate with a nasal decongestant and pain reliever. It is indicated for treatment of allergies, sinus congestion and pressure, runny nose and sneezing, itchy, watery eyes, and itchy throat. The product began shipping to stores nationwide immediately upon FDA approval and will be found on store shelves within weeks. Tavist Allergy/Sinus/Headache, as with all Tavist products, is PPA-free, utilizing pseudoephedrine hydrochloride as the active decongestant ingredient. The Tavist brand line also includes Tavist® Sinus and Tavist® Allergy. Tavist brand products have been marketed over the counter in the U.S. since 1992. "With the launch of Tavist Allergy/Sinus/Headache, for the first time consumers can now choose a Tavist product that will provide complete relief of their allergy and sinus symptoms, as well as pain relief," said Barry Cohen, North American OTC Category Vice President for Novartis Consumer Health. "Consumers have placed a high level of trust and confidence in Tavist over-the-counter medications for nearly a decade, and we are certain this new Tavist product will provide them with the same quality of care they have come to expect." Related Link: Novartis. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.